Exploring a novel mechanism for targeting β-arrestin-2 in the management of diabetic nephropathy

doi:10.4239/wjd.v16.i4.101994

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=0

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=0

Apr 15, 2025 (publication date) through Feb 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Apr 15, 2025; 16(4): 101994
Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.101994

Exploring a novel mechanism for targeting β-arrestin-2 in the management of diabetic nephropathy

Na Liu, Wei-Tao Yan, Kun Xiong

Na Liu, Wei-Tao Yan, Kun Xiong, Department of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha 410013, Hunan Province, China

Author contributions: Liu N wrote the original draft; Yan WT reviewed and edited the manuscript; Xiong K was the senior author and provided supervision and validation of the writing; All authors have read and agreed to the published version of the manuscript.

Supported by National Natural Science Foundation of China, No. 82303047, No. 82372507, No. 82172196 and No. 32401046; and Natural Science Foundation of Hunan Province, No. 2022JJ40801.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Kun Xiong, PhD, Professor, Department of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, No. 172 Tongzipo Road, Changsha 410013, Hunan Province, China. xiongkun2001@163.com

Received: October 14, 2024
Revised: January 4, 2025
Accepted: February 10, 2025
Published online: April 15, 2025
Processing time: 139 Days and 21.3 Hours

Core Tip

Core Tip: Diabetic nephropathy (DN), a complication of diabetes mellitus, poses significant challenges in the management. Liu et al observed that β-arrestin-2 deteriorates DN through inducing endoplasmic reticulum (ER) stress, and inhibiting β-arrestin-2 may protect glomerular endothelial cells and mitigate DN progression by curbing ER stress. This research underscores the significance of ER stress in DN and reveals an innovative molecular pathway involving β-arrestin-2 that may contribute to DN progression, offering potential targets for therapeutic interventions. Nevertheless, further clinical validation and investigation are necessary to confirm the clinical application of these findings.